Citations

Showing 10 of 108162 citations.

Benefits of Heuristic and Bias Awareness in Medical Education
Sussman, Jon , Sussman, Jon D

Mayo Clinic

Academic Medicine | November 27, 2019 | Volume: 94 | Issue: 12 | Pages: 1845-1845

10.1097/acm.0000000000002975 | PMID 31789857 Get It

A Novel Allergen-Specific Immune Signature-Directed Approach to Dietary Elimination in Eosinophilic Esophagitis
Dellon, Evan S. , Guo, Rishu , McGee, Sarah J., Hamilton, Deanna, Nicolai, Emily, Covington, Jacquelyn, Moist, Susan E., Arrington, Ashley, Wright, Benjamin L. , Vickery, Brian P. , Wright, Benjamin L , Burks, A. Wesley , Kulis, Michael D.

Mayo Clinic

Clinical and Translational Gastroenterology | November 27, 2019 | Volume: 10 | Issue: 12 | Pages: e00099

10.14309/ctg.0000000000000099 | PMID 31789931 Get It

OBJECTIVES: Dietary elimination for treatment of eosinophilic esophagitis (EoE) is limited by lack of accuracy in current allergy tests. We aimed to develop an immunologic approach to identify dietary triggers and prospectively test allergen-specific immune signature-guided dietary elimination therapy. METHODS: In the first phase, we developed and assessed 2 methods for determining selected food triggers using samples from 24 adults with EoE: a CD4+ T-cell proliferation assay in peripheral blood and food-specific tissue IgG4 levels in esophageal biopsies. In the second phase, we clinically tested elimination diets created from these methods in a prospective cohort treated for 6 weeks (NCT02722148). Outcomes included peak eosinophil counts (eos/hpf), endoscopic findings (measured by the EoE Endoscopic Reference Score), and symptoms (measured by the EoE Symptom Activity Index). RESULTS: Parameters were optimized with a positive test on either assay, yielding agreements of 60%, 75%, 53%, 58%, and 53% between predicted and known triggers of peanut, egg, soy, wheat, and milk, respectively. In clinical testing, the mean number of foods eliminated based on the assays was 3.4, and 19 of 22 subjects were compliant with treatment. After treatment, median peak eosinophil counts decreased from 75 to 35 ( P = 0.007); there were 4 histologic responders (21%). The EoE Endoscopic Reference Score and EoE Symptom Activity Index score also decreased after treatment (4.6 vs 3.0; P = 0.002; and 32.5 vs 25.0; P = 0.06, respectively). DISCUSSION: We successfully developed a new testing approach using CD4 + T-cell proliferation and esophageal food-specific IgG4 levels, with promising accuracy rates. In clinical testing, this led to improvement in eosinophil counts, endoscopic severity, and symptoms of dysphagia, but a smaller than expected number of patients achieved histologic remission.
Hospital Digest Section
Marks, Richard V., Emrich, Richard S., Reitzes, Dietrich C., Horak, Emil I., Kerfoot, Glenn, McComb, Stanley J., Schroder, Donald M.

Mayo Clinic

Hospital Topics | November 27, 2019 | Volume: 41 | Issue: 9 | Pages: 19-26

10.1080/00185868.1963.12082652 Get It

Superior Intellectual Outcomes After Proton Radiotherapy Compared With Photon Radiotherapy for Pediatric Medulloblastoma
Kahalley, Lisa S. , Ris, M. Douglas , Janzen, Laura , Okcu, M. Fatih , Grosshans, David R. , Mahajan, Anita , Tsang, Derek S. , Whitehead, William E. , Dauser, Robert C., Conklin, Heather M. , Chintagumpala, Murali , Kahalley, Lisa S , Peterson, Rachel K. , Ramaswamy, Vijay , Paulino, Arnold C. , Hodgson, David , Laperrière, Normand , Taylor, Michael D. , Bouffet, Éric , Mabbott, Donald

Mayo Clinic

Journal of Clinical Oncology | November 27, 2019 | Volume: 38 | Issue: 5 | Pages: 454-461

10.1200/jco.19.01706 | PMID 31774710 Get It

PURPOSE Proton radiotherapy (PRT) may lessen the neuropsychological risk traditionally associated with cranial radiotherapy for the treatment of pediatric brain tumors by reducing the dose to normal tissue compared with that of photon radiotherapy (XRT). We examined the change in intellectual scores over time in patients with pediatric medulloblastoma treated with craniospinal PRT versus XRT. METHODS Intelligence test scores were obtained for a sample of pediatric patients treated between 2007 and 2018 on the same medulloblastoma protocols that differed only in radiotherapy modality (PRT v XRT). Growth curve analyses compared change in scores over time since diagnosis between groups. RESULTS Longitudinal intelligence data from 79 patients (37 PRT, 42 XRT) were examined. Groups were similar on most demographic/clinical variables, including sex (67.1% male), age at diagnosis (mean, 8.6 years), craniospinal irradiation dose (median, 23.4 Gy), length of follow-up (mean, 4.3 years), and parental education (mean, 14.3 years). Boost dose ( P < .001) and boost margin ( P = .001) differed between groups. Adjusting for covariates, the PRT group exhibited superior long-term outcomes in global intelligence quotient (IQ), perceptual reasoning, and working memory compared with the XRT group (all P < .05). The XRT group exhibited a significant decline in global IQ, working memory, and processing speed (all P < .05). The PRT group exhibited stable scores over time in all domains with the exception of processing speed ( P = .003). CONCLUSION To our knowledge, this is the first study to compare intellectual trajectories between pediatric patients treated for medulloblastoma with PRT versus those treated with XRT on comparable, contemporary protocols. PRT was associated with more favorable intellectual outcomes in most domains compared with XRT, although processing speed emerged as a vulnerable domain for both groups. This study provides the strongest evidence to date of an intellectual sparing advantage with PRT in the treatment of pediatric medulloblastoma.
Essential Thrombocythemia
Tefferi, Ayalew , Pardanani, Animesh

Mayo Clinic

New England Journal of Medicine | November 27, 2019 | Volume: 381 | Issue: 22 | Pages: 2135-2144

10.1056/nejmcp1816082 | PMID 31774958 Get It

Can the Misinterpretation Amendment Rate Be Used as a Measure of Interpretive Error in Anatomic Pathology?: Implications of a Survey of the Directors of Anatomic and Surgical Pathology
Fadare, Oluwole , Dewar, Rajan , Nakhleh, Raouf E. , Cooper, Kumarasen , Parkash, Vinita, Parkash, Vinita

Mayo Clinic

Advances in Anatomic Pathology | November 27, 2019 | Volume: 24 | Issue: 2 | Pages: 82-87

10.1097/pap.0000000000000142 | PMID 28181951 Get It

A repeat survey of the Association of the Directors of Anatomic and Surgical Pathology, done 10 years after the original was used to assess trends and variability in classifying scenarios as errors, and the preferred post signout report modification for correcting error by the membership of the Association of the Directors of Anatomic and Surgical Pathology. The results were analyzed to inform on whether interpretive amendment rates might act as surrogate measures of interpretive error in pathology. An analyses of the responses indicated that primary level misinterpretations (benign to malignant and vice versa) were universally qualified as error; secondary-level misinterpretations or misclassifications were inconsistently labeled error. There was added variability in the preferred post signout report modification used to correct report alterations. The classification of a scenario as error appeared to correlate with severity of potential harm of the missed call, the perceived subjectivity of the diagnosis, and ambiguity of reporting terminology. Substantial differences in policies for error detection and optimal reporting format were documented between departments. In conclusion, the inconsistency in labeling scenarios as error, disagreement about the optimal post signout report modification for the correction of the error, and variability in error detection policies preclude the use of the misinterpretation amendment rate as a surrogate measure for error in anatomic pathology. There is little change in uniformity of definition, attitudes and perception of interpretive error in anatomic pathology in the last 10 years.
The GRIT (Gather, Restate, Inquire, Talk It Out) Framework for Addressing Microaggressions
Njathi-Ori, Catherine W., O’Brien, Erin K. , O'Brien, Erin K , Warner, Nafisseh S. , Njathi-Ori, Catherine

Mayo Clinic

JAMA Surgery | November 27, 2019 | Volume: 155 | Issue: 2 | Pages: 178

10.1001/jamasurg.2019.4427 | PMID 31774484 Get It

OBG: Study affirms benefits of Post-partum tub baths?
Smith, Reginald Armitage, Hodgson, Jane E.

Mayo Clinic

Hospital Topics | November 27, 2019 | Volume: 44 | Issue: 10 | Pages: 101-102

10.1080/00185868.1966.12083415 Get It

Subcutaneous mixed lobular and septal panniculitis with numerous eosinophils associated with autologous fat grafting: Expanding the differential diagnosis of eosinophilic panniculitis
Logunova, Valentina , Bridges, Alina G.

Mayo Clinic

Journal of Cutaneous Pathology | November 27, 2019 | Volume: 47 | Issue: 3 | Pages: 305-307

10.1111/cup.13619 | PMID 31774571 Get It

An Open‐Label, Dose‐Escalation Study to Assess the Safety and Efficacy of IL‐22 Agonist F‐652 in Patients With Alcohol‐associated Hepatitis
Arab, Juan Pablo , Sehrawat, Tejasav S. , Simonetto, Douglas A. , Verma, Vikas , Feng, Dechun , Tang, Tom , Dreyer, Kevin, Yan, Xiaoqiang , Daley, William, Chalasani, Naga , Radaeva, Svetlana , Yang, Liu , Vargas, Hugo E. , Ibacache, Mauricio , Kamath, Patrick S. , Shah, Vijay H. , Arab, Juan P , Verma, Vikas K, Vargas, Hugo, Malhi, Harmeet , Shah, Vijay H , Vargas, Hugo E , Sehrawat, Tejasav S , Simonetto, Douglas A , Sanyal, Arun J. , Gao, Bin , Gores, Gregory J. , Malhi, Harmeet , Yang, Liu

Mayo Clinic

Hepatology | November 27, 2019 | Volume: 72 | Issue: 2 | Pages: 441-453

10.1002/hep.31046 | PMID 31774566 Get It

Background and Aims Interleukin‐22 has beneficial effects on inflammation and impaired hepatic regeneration that characterize alcohol‐associated hepatitis (AH). F‐652 is a recombinant fusion protein of human interleukin‐22 and immunoglobulin G2 fragment crystallizable. This study aims to assess the safety and efficacy signals of F‐652 in patients with moderate and severe AH. Approach and Results A phase‐2 dose‐escalating study was carried out. F‐652 (10 μg/kg, 30 μg/kg, or 45 μg/kg) administered on days 1 and 7 was tested in 3 patients each with moderate (Model for End‐Stage Liver Disease [MELD] scores: 11‐20) and severe AH (MELD scores: 21‐28). Safety was defined by absence of serious adverse events and efficacy was assessed by Lille score, changes in MELD score, and serum bilirubin and aminotransferases at days 28 and 42. Three independent propensity‐matched comparator patient cohorts were used. Plasma extracellular vesicles and multiplex serum cytokines were measured to assess inflammation and hepatic regeneration. Eighteen patients (9 moderate and 9 severe AH) were enrolled, 66% were male, and the mean age was 48 years. The half‐life of F‐652 following the first dose was 61‐85 hours. There were no serious adverse events leading to discontinuation. The MELD score and serum aminotransferases decreased significantly at days 28 and 42 from baseline (P < 0.05). Day‐7 Lille score was 0.45 or less in 83% patients as compared with 6%, 12%, and 56% among the comparator cohorts. Extracellular vesicle counts decreased significantly at day 28 (P < 0.013). Cytokine inflammatory markers were down‐regulated, and regeneration markers were up‐regulated at days 28 and 42. Conclusions F‐652 is safe in doses up to 45 μg/kg and associated with a high rate of improvement as determined by Lille and MELD scores, reductions in markers of inflammation and increases in markers of hepatic regeneration. This study supports the need for randomized placebo‐controlled trials to test the efficacy of F‐652 in AH.